Acute treatment of bipolar disorder with adjunctive risperidone in outpatients.
To test the hypothesis that, although typical neuroleptics are commonly used in the treatment of bipolar disorder, newer atypical antipsychotic agents, like risperidone, may be more effective and better-tolerated. The effectiveness of risperidone was evaluated in 14 outpatients with bipolar disorder, type I, who received risperidone for 6.4 +/- 2.7 weeks at 2.75 +/- 1.8 mg/day. Nine (64%) patients were much improved based on Clinical Global Impression (CGI) scores, and mean Global Assessment of Functioning (GAF) scores improved from 48.2 +/- 4.9 to 58.8 +/- 7.3 (t = 4.49, P = 0.0006, paired t test). Treatment was well tolerated, and no patient experienced worsening of mood symptoms while receiving risperidone. This open series suggests risperidone is beneficial in the treatment of outpatients with bipolar disorder.